(+) 3,4-Methylenedioxymethamphetamine ('Ecstasy') transiently increases striatal 5-HT(1B) binding sites without altering 5-HT(1B) mRNA in rat brain

Molecular Psychiatry

Volumn 4, Issue 6, 1999, Pages 572-579

  Sexton, T J ^a   McEvoy, C ^a   Neumaier, J F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Citalopram; In situ hybridization; Iodocyanopindolol; MDMA; Neurotoxicity; Serotonin; Striatum

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BRAIN RECEPTOR; CITALOPRAM; CYANOIODOPINDOLOL; MESSENGER RNA; SEROTONIN 1B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BINDING SITE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DORSAL RAPHE NUCLEUS; DOWN REGULATION; HIPPOCAMPUS; IN SITU HYBRIDIZATION; ISOTOPE LABELING; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032760276     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000574     Document Type: Article

References (27)

1. 1 McKenna DJ, Peroutka SJ. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). J Neurochem 1990; 54: 14-22.
2. 2 Mamounas LA, Mullen GA, O'Hearn E, Molliver ME. Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 1991; 314: 558-586.
3. 3 Gartside SE, McQuade R, Sharp T. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: comparison between dorsal and median raphe 5-HT systems. Neuropharmacology 1997; 36: 1697-1703.
4. 4 Rudnick G, Wall SC. The molecular mechanism of 'ecstasy' [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets from MDMA-induced serotonin release. Proc Natl Acad Sci USA 1992; 89: 1817-1821.
5. 5 Ricaurte GA, Markowska AL, Wenk GL, Hatzidimitriou G, Wlos J, Olton DS. 3,4-methylenedioxymethamphetamine, serotonin and memory. J Pharmacol Exp Ther 1993; 266: 1097-1105.
6. 6 Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR et al. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 1993; 15: 91-96.
7. 7 Battaglia G, Sharkey J, Kuhar MJ, de Souza EB. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse 1991; 8: 249-260.
8. 8 Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA. Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 1993; 264: 1484-1491.
9. 9 Insel TR, Battaglia G, Johannessen JN, Marra S, De S-EB. 3,4-Methylenedioxymethamphetamine ('ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989; 249: 713-720.
10. 10 Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616-622.
11. 1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 1993; 8: 201-211.
12. 1B agonist. J Pharmacol Exp Ther 1992; 263: 318-326.
13. 1B, serotonin receptors. Nature Genet 1996; 13: 98-101.
14. 14 Rocha BA, Scearce L-K, Lucas JJ, Hiroi N, Castanon N, Crabbe JC et al. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 1998; 393: 175-178.
15. 1B receptor is localized predominantly on axon terminals. Neuroscience 1994; 58: 167-182.
16. 16 Hoyer D, Middlemiss DN. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci 1989; 10: 130-132.
17. 1D receptor subtypes. Trends Pharmacol Sci 1996; 17: 103-105.
18. 18 McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 1991; 11: 302-305.
19. 19 McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br J Psychiatry 1994; 165: 391-395.
20. 20 Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1b mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology 1996; 15: 515-522.
21. 21 Neumaier JF. Quantitative in situ hybridization detection of 5-HT receptor mRNA in rat brain using storage phosphor imaging. Am Biotech Lab 1998; 16: 61-62.
22. 1B receptor mRNA levels in rat brain. Brain Res 1996; 722: 50-58.
23. 1B receptor binding sites in the central nervous system. Neuropsychopharmacology 1994; 10: 259-264.
24. 1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 1992; 7: 113-127.
25. 1B receptors in the brain of the rat. J Pharm Exp Ther 1988; 244: 144-153.
26. 26 Geyer MA. Serotonergic functions in arousal and motor activity. Behav Brain Res 1995; 73: 1-2.
27. 1B receptor stimulation enhances cocaine reinforcemet. J Neurosci 1998; 18: 10078-10089.